Role of GABAergic system in the pathogenesis and treatment of Tourette syndrome in children

doi:10.11852/zgetbjzz2024-0307

Abstract

Abstract: Childhood Tourette syndrome(TS) is a chronic neuropsychiatric disorder with a prevalence of about 1% in children and adolescents. Its clinical features include sudden, involuntary twitching symptoms such as eye blinking, head shaking, and tics involving other muscles of the face, trunk, and limbs, as well as vocal tics. At present, the pathogenesis of TS is currently not clear, and there is no effective treatment for TS. γ-aminobotyric acid(GABA) is the primary inhibitory neurotransmitter in the mammalian brain. Some studies have shown that the imbalance of GABAergic system is involved in the occurrence and development of many neuropsychiatric diseases. In recent years, the role of GABAergic system in TS has gained much attention. Current research focuses on the abnormality of GABAergic metabolic pathway and the changes of GABA metabolism of intestinal flora in TS patients. However, there are no specific GABAergic drugs developed for the treatment of TS. This review provides insights into the role of the GABAergic system in the pathophysiology of TS and its potential as a novel therapeutic target.

Key words: Tourette syndrome, γ-aminobotyric acid, GABAergic system, brain-gut axis

摘要： Tourette综合征(TS)是一种儿童和青少年中患病率约为 1%的慢性神经精神障碍性疾病。临床特征为眨眼、摇头等头面以及躯干、四肢等部位骨骼肌的突发的、不自主性的抽动症状和发声抽搐。目前TS的发病机制不明,尚缺乏有效的治疗手段。γ-氨基丁酸(GABA)是哺乳动物大脑中主要的抑制性神经递质。有研究显示,GABA能系统的失衡参与了多种神经精神疾病的发生发展。近年来,GABA能系统在TS中的作用被大家关注。目前研究集中在GABA能代谢途径的异常以及TS患者肠道菌群GABA代谢的变化。但目前没有特定治疗TS的GABA能系统药物。该文提供了关于GABA能系统在TS病理生理学中的作用以及其作为新治疗的潜在靶点。

关键词: 多发性抽动症, γ-氨基丁酸, GABA能系统, 脑肠轴

CLC Number:

R749.94

XU Ying, SHI Haishui, ZHANG Huifeng, TIAN Xiaoyu. Role of GABAergic system in the pathogenesis and treatment of Tourette syndrome in children[J]. Chinese Journal of Child Health Care, 2024, 32(10): 1101-1105.

许莹, 史海水, 张会丰, 田晓瑜. GABA能系统在Tourette综合征中的作用及治疗展望[J]. 中国儿童保健杂志, 2024, 32(10): 1101-1105.

References

[1] Robertson NP. Advances in Tourette′s syndrome[J]. J Neurol, 2023, 270(3): 1808-1810.
[2] Yu D, Sul JH, Tsetsos F, et al. Interrogating the genetic determinants of Tourette′s syndrome and other tic disorders through genome-wide association studies[J]. Am J Psychiatry, 2019, 176(3): 217-227.
[3] Mahjani B, Bey K, Boberg J, et al. Genetics of obsessive-compulsive disorder[J]. Psychol Med, 2021, 51(13): 2247-2259.
[4] Pedersen JH, Skytthe A, Bybjerg-Grauholm J, et al. Concordance and comorbidities among monozygotic twins with tic disorders[J]. J Psychiatr Res, 2022, 146: 297-303.
[5] Wang X, Liu X, Chen L, et al. The inflammatory injury in the striatal microglia-dopaminergic-neuron crosstalk involved in Tourette syndrome development[J]. Front Immunol, 2023, 14: 1178113.
[6] Israelashvili M, Yael D, Vinner E, et al. Common neuronal mechanisms underlying tics and hyperactivity[J]. Cortex, 2020, 127: 231-247.
[7] Schilke E D, Tremolizzo L, Appollonio I, et al. Tics: Neurological disorders determined by a deficit in sensorimotor gating processes[J]. Neurol Sci, 2022, 43(10): 5839-5850.
[8] Chen M, Ruan G, Chen L, et al. Neurotransmitter and intestinal interactions: Focus on the microbiota-gut-brain axis in irritable bowel syndrome[J]. Front Endocrinol (Lausanne), 2022, 13: 817100.
[9] Peerboom C, Wierenga C J. The postnatal GABA shift: A developmental perspective[J]. Neurosci Biobehav Rev, 2021, 124: 179-192.
[10] Luscher B, Maguire J L, Rudolph U, et al. GABA(A) receptors as targets for treating affective and cognitive symptoms of depression[J]. Trends Pharmacol Sci, 2023, 44(9): 586-600.
[11] Koh W, Kwak H, Cheong E, et al. GABA tone regulation and its cognitive functions in the brain[J]. Nat Rev Neurosci, 2023, 24(9): 523-539.
[12] Sears SM, Hewett SJ. Influence of glutamate and GABA transport on brain excitatory/inhibitory balance[J]. Exp Biol Med (Maywood), 2021, 246(9): 1069-1083.
[13] Tanaka K. Astroglia and obsessive compulsive disorder[J]. Adv Neurobiol, 2021, 26: 139-149.
[14] Johnson KA, Worbe Y, Foote KD, et al. Tourette syndrome: clinical features, pathophysiology, and treatment[J]. Lancet Neurol, 2023, 22(2): 147-158.
[15] Favuzzi E, Huang S, Saldi GA, et al. GABA-receptive microglia selectively sculpt developing inhibitory circuits[J]. Cell, 2021, 184(15): 4048-4063.e32.
[16] Cothros N, Medina A, Pringsheim T. Current pharmacotherapy for tic disorders[J]. Expert Opin Pharmacother, 2020, 21(5): 567-580.
[17] Shitovaa D, Zharikova TS, Kovaleva ON, et al. Tourette syndrome and obsessive-compulsive disorder: A comprehensive review of structural alterations and neurological mechanisms[J]. Behav Brain Res, 2023, 453: 114606.
[18] Israelashvili M, Yael D, Vinner E, et al . Common neuronal mechanisms underlying tics and hyperactivity[J]. Cortex, 2020,127:231-247.
[19] Worbe Y, Marrakchi-Kacem L, Lecomte S, et al. Altered structural connectivity of cortico-striato-pallido-thalamic networks in Gilles de la Tourette syndrome[J]. Brain, 2015, 138(Pt 2): 472-482.
[20] Lennington JB, Coppola G, Kataoka-Sasaki Y, et al. Transcriptome analysis of the human striatum in Tourette syndrome[J]. Biol Psychiatry, 2016, 79(5): 372-382.
[21] Barbour AJ, Gourmaud S, Lancaster E, et al. Seizures exacerbate excitatory: inhibitory imbalance in Alzheimer′s disease and 5XFAD mice[J]. Brain, 2024,147(6):2169-2184.
[22] Zhang W, Yu W, Liu X, et al. Effect of Jian-Pi-Zhi-Dong decoction on the amino acid neurotransmitters in a rat model of Tourette syndrome and comorbid anxiety disorder[J]. Front Psychiatry, 2020, 11: 515.
[23] Xiao L, Priest MF, Nasenbeny J, et al. Biased oxytocinergic modulation of midbrain dopamine systems[J]. Neuron, 2017, 95(2): 368-384.e5.
[24] Cadeddu R, Knutson DE, Mosher LJ, et al. The α6 GABA(A) receptor positive allosteric modulator DK-I-56-1 reduces tic-related behaviors in mouse models of Tourette syndrome[J]. Biomolecules, 2021,11(2):175.
[25] Draper A, Stephenson MC, Jackson GM, et al. Increased GABA contributes to enhanced control over motor excitability in Tourette syndrome[J]. Curr Biol, 2014, 24(19): 2343-2347.
[26] 于文静,白雪,张雯,等.健脾止动汤对多发性抽动症患儿神经递质的影响[J].中华中医药杂志,2015,30(5):1757-1761.
Yu WJ, Bai X, Zhang W, et al. Effect of spleen-enhancing and stopping action soup on neurotransmitters in children with multiple tic disorders[J]. Chinese Medicine Miscellany, 2015,30(5):1757-1761.(in Chinese)
[27] Liu S, Tian M, He F, et al. Mutations in ASH1L confer susceptibility to Tourette syndrome[J]. Mol Psychiatry, 2020, 25(2): 476-490.
[28] Qin L, Williams JB, Tan T, et al. Deficiency of autism risk factor ASH1L in prefrontal cortex induces epigenetic aberrations and seizures[J]. Nat Commun, 2021, 12(1): 6589.
[29] Tsetsos F, Yu D, Sul JH, et al. Synaptic processes and immune-related pathways implicated in Tourette syndrome[J]. Transl Psychiatry, 2021, 11(1): 56.
[30] Dicks LMT. Gut Bacteria and neurotransmitters[J]. Microorganisms, 2022,10(9):1838.
[31] Serrano-Castro P J, Rodríguez-Uranga JJ, Cabezudo-García P, et al. Cenobamate and clobazam combination as personalized medicine in autoimmune-associated epilepsy with anti-Gad65 antibodies[J]. Neurol Neuroimmunol Neuroinflamm,2023,10(6):e200151.
[32] Liao Y, Fan L, Bin P, et al. GABA signaling enforces intestinal germinal center B cell differentiation[J]. Proc Natl Acad Sci U S A, 2022, 119(44): e2215921119.
[33] Zhao H, Shi Y, Luo X, et al. The effect of fecal microbiota transplantation on a child with Tourette syndrome[J]. Case Rep Med, 2017, 2017: 6165239.
[34] Xi W, Gao X, Zhao H, et al. Depicting the composition of gut microbiota in children with tic disorders: An exploratory study[J]. J Child Psychol Psychiatry, 2021, 62(10): 1246-1254.
[35] Sanchez M, Fernández J, Martin M, et al. Purification and properties of two succinic semialdehyde dehydrogenases from Klebsiella pneumoniae[J]. Biochim Biophys Acta, 1989, 990(3): 225-231.
[36] Strandwitz P, Kim KH, Terekhova D, et al. GABA-modulating bacteria of the human gut microbiota[J]. Nat Microbiol, 2019, 4(3): 396-403.
[37] Yunes RA, Poluektovae U, Dyachkovam S, et al. GABA production and structure of gadB/gadC genes in Lactobacillus and Bifidobacterium strains from human microbiota[J]. Anaerobe, 2016, 42: 197-204.
[38] Hartmann A. Clinical pharmacology of nondopaminergic drugs in Tourette syndrome[J]. Int Rev Neurobiol, 2013, 112: 351-372.
[39] Awaad Y. Tics in Tourette syndrome: New treatment options[J]. J Child Neurol, 1999, 14(5): 316-319.
[40] Singer HS, Wendlandt J, Krieger M, et al. Baclofen treatment in Tourette syndrome: A double-blind, placebo-controlled, crossover trial[J]. Neurology, 2001, 56(5): 599-604.
[41] Giyyis AH, Leventhal DK, Fensterheim BA, et al. Selective inhibition of striatal fast-spiking interneurons causes dyskinesias[J]. J Neurosci, 2011, 31(44): 15727-15731.
[42] 胡屹伟,巩利,李林文.肌苷和γ-氨基丁酸治疗抽动-秽语综合征疗效观察[J].山东医药,1995,39(7):12.
Hu YW,Gong L,Li LW. Observation on the efficacy of inosine and gamma-aminobutyric acid in the treatment of Tourette′s syndrome[J]. Shandong Medicine,1995,39(7):12.(in Chinese)